This genotype is generally associated with typical or slightly lower endogenous IGF-1 production, which may result in a more modest anabolic response to growth-factor signaling
CagriSema's Advantages: First to Market: 6-12 month head start Leverages Wegovy Success: Built-in brand recognition Proven Semaglutide Component: Half the drug is already approved Strong Diabetes Data: Positions for dual indication No Dysesthesia: Cleaner safety profile in one key area Retatrutide's Advantages: Higher Efficacy: 28.7% vs 20.4% (8.3 points more) Superior BP Reduction: -14 mmHg vs likely similar to semaglutide Single Molecule: Potentially easier manufacturing Multiple Indications: OA, OSA, obesity, diabetes trials Novel Class: First triple agonist = strong IP protection The Verdict: Market Will Support Both These medications won't compete head-to-head
In fact, many customers use both Face Tonic and Hair Tonic daily across their face and scalp for comprehensive peptide support
References Lennerz BS, Mey JT, Henn OH, Ludwig DS
(2012) has investigated the role of miRNAs as a mechanism of decreased IGF-1R level during the postnatal period
Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation
